CLINICAL TRIAL

Treadmill walking for Parkinson Disease

Recruiting · 18+ · All Sexes · Columbus, OH

This study is evaluating whether a high intensity exercise program may help reduce the progression of Parkinson's disease.

See full description

About the trial for Parkinson Disease

Treatment Groups

This trial involves 2 different treatments. Treadmill Walking is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Treadmill walking
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Treadmill walking
BEHAVIORAL

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Treadmill walking
2008
N/A
~90

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
This patient has been diagnosed with idiopathic Parkinson's Disease (PD) based on the modified United Kingdom PD brain bank criteria show original
years The text is about the Hoehn and Yahr stages of Parkinson's disease show original
The disease has been present for less than three years. show original
Age 40-80 years
The positive DaTscan™ SPECT by quantitative readout can be used to diagnose idiopathic Parkinson disease. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 18 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 18 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 18 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treadmill walking will improve 10 secondary outcomes and 2 other outcomes in patients with Parkinson Disease. Measurement will happen over the course of 12 months.

Initiation of dopaminergic therapy
12 MONTHS
Time to initiation of dopaminergic therapy
12 MONTHS
Change in dopaminergic activity
12 MONTHS
Change from baseline in the striatal specific binding ratio (SSBR) as measured by dopamine transporter imaging
12 MONTHS
Change in activity
18 MONTHS
Change from baseline in the number of steps
18 MONTHS
Change in walking capacity
18 MONTHS
Change from baseline in distance in 6-minute walk
18 MONTHS
Change in stride length
18 MONTHS
Change in stride length assessed using OPAL movement monitors during the 6 minute walk test
18 MONTHS
Change in blood derived marker of neuronal development
18 MONTHS
Change from baseline in brain derived neurotrophic factor (BDNF)
18 MONTHS
See More

Who is running the study

Principal Investigator
D. C.
Prof. Daniel Corcos, Professor of Physical Therapy and Human Movement Sciences
Northwestern University

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get parkinson disease a year in the United States?

Approximately 175,000 new cases of Parkinson disease are diagnosed in the Unites States each year. By age 75, roughly 40% of patients diagnosed with Parkinson disease develop significant disability. In many respects, the disease onset is insidious, but most patients present themselves as early as age 40, often with significant cognitive deterioration and motor disability. In the United States, approximately 1 out of 25 Americans over age 75 is diagnosed with the disorder. The number of affected individuals is estimated to be more than 3.5 million.

Anonymous Patient Answer

What is parkinson disease?

An estimated one out of every 70 people will eventually develop Parkinson's disease. It is considered a degenerative disorder that develops in individuals over the age of sixty. The onset of Parkinson's disease begins in the late teens or 20s, although symptoms may not become noticeable until the second decade of life is over. Parkinson's disease patients often have a lower quality of life when they have a disease that doesn't respond to current medication or a surgery or transplant. In the United States, over 50,000 new cases of Parkinson's disease occur each year. Also over 50,000 deaths in the United States. The U.S. is one of the most expensive of developed nations for people who have a degenerative neurological disorder.

Anonymous Patient Answer

What are the signs of parkinson disease?

Muscle weakness and rigidity are the most common PD symptoms. The other PD symptoms that occur are speech disturbances, postural instability and gait abnormality. People with PD can also have eye movement disorders (levodopa-induced dyskinesia and daytime sleepiness), sleep disturbances ([apnea, periodic limb movements in sleep, and snoring]<nowiki>],</nowiki> fatigue, depression, and anxiety. You can find the most recent PD clinical trials by using Power to search for trials that are closest to you. [Power](http://www.withpower.

Anonymous Patient Answer

What causes parkinson disease?

The cause of sporadic Parkinson disease is unknown, but some people are affected because they have a mutation in a gene that makes a protein that protects against the disease, probably by restricting the buildup of a particular group of pollutants. Other risk factors that increase the incidence of the disorder might be due to changes in lifestyle, or in the environment.

Anonymous Patient Answer

What are common treatments for parkinson disease?

In Japan, most cases of PD are treated with medications, but several medical treatments like brain and spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and transcranial magnetic stimulation are also used. In Western countries, deep brain stimulation and vagus nerve stimulation are often used as well. In clinical practice, it is not always possible to tell the difference between the efficacy of the treatment and the side-effect profile of the medicine.

Anonymous Patient Answer

Can parkinson disease be cured?

Parkinson disease is not a form of primary degeneration, but a complex genetic disorder that can be partially prevented by genetic testing. People with Parkinson's and people at high-risk of it should take urgent action to halt or slow their disease.

Anonymous Patient Answer

How does treadmill walking work?

The improvements of gait parameters after the treadmill training were not significant. No difference between groups in terms of muscle strength was observed either (95.

Anonymous Patient Answer

Has treadmill walking proven to be more effective than a placebo?

Recent findings confirms the conclusions made using both placebo and placebo controlled trials, as walking on an exercise treadmill does not enhance motor function for an individual with a sub-acute or chronic LBD. The duration of these interventions do not appear to be important in influencing recovery, as patients who participated in an intensive exercise regimen for 4 weeks did not benefit significantly from a 2-week walking exercise program. However, the study is limited in that no control group was used and no post assessments were carried out after 12 weeks.

Anonymous Patient Answer

What does treadmill walking usually treat?

While the therapeutic effectiveness of treadmill walking has been reported in several studies, these findings do not necessarily equate to improved quality of life or mobility, but rather reflect the response of symptoms to treatments. Patients with gait, balance, and mobility difficulties report the improvements from treadmill walking and rehabilitation, without any improvement in the mobility difficulties.

Anonymous Patient Answer

What are the latest developments in treadmill walking for therapeutic use?

The first walking therapy was invented in 1960s in the US by Dr. Milton H. Rosenberg (1950-2011). Treadmill work is often cited as helping participants with different medical conditions regain or maintain fitness, and as a way for disabled people to regain, or maintain, motion and strength in their hands and legs. The first report about treadmill therapy in the US for those who had Parkinson's was published in 1990. Since then treadmill therapy has been applied to those with various other health conditions with varying success. There are many reports of treadmill therapy in many other countries but there are limited articles about the applications for rehabilitation people in Europe or Canada or Mexico or Australia or New Zealand.

Anonymous Patient Answer

How serious can parkinson disease be?

The majority of patients are well, but 2% have moderate disability and 7% have severe disability, indicating the importance of early diagnosis and symptom management. The majority of patients use medication and/or receive deep-brain stimulation, although these treatments are generally insufficient for most. Recent findings strongly suggest that neuroleptic malignant syndrome does not occur regularly, but may do so from time to time, despite the high doses of neuroleptics. More than 70% of symptoms improved upon use of a specific antipsychotic, demonstrating the possible efficacy of this type of therapy.

Anonymous Patient Answer

What is the latest research for parkinson disease?

Since there is minimal current research that is applicable to the elderly with PD over the age of 65, the primary focus of study in PD must be on therapies that are used in PD that still have potential in the elderly.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Parkinson Disease by sharing your contact details with the study coordinator.